Bioreliance
Bioreliance is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus
Sponsor Cabaletta Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-02)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Bioreliance?
The 2026-10-09 snapshot links Bioreliance to 4 distinct CTIS trials. Recorded services include CABA-201 Manufacturer, Drug Substance: Release testing, Stability testing, Drug Substance: Release Testing, Stability Testing, Drug Substance: Testing cell banks for viruses, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Bioreliance?
The most frequently recorded therapeutic areas are Hepatology, Immunology, Nephrology, Rheumatology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Bioreliance conducted?
The linked trials record locations in 7 countries, including Spain, Germany, Italy, Bulgaria, France. These are trial locations, not confirmed office locations or countries where Bioreliance delivered services.
What can this page tell me about Bioreliance's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Bioreliance. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Bioreliance Corp.
- Bioreliance Limited